VistaGen Therapeutics Inc (VTGN)

[StockLogistics]

“While we examine the results of our PALISADE-1 Phase 3 study in social anxiety disorder, we have paused enrollment in our PALISADE-2 Phase 3 study and have engaged an independent biostatistician to conduct an interim analysis of data collected to date. We then plan to meet with the FDA to pursue a consensus path forward for further Phase 3 development of PH94B in social anxiety disorder.”

They have safety but no efficacy, I think this company might be heading to bankruptcy, the SP held up as the bollinger band crossed from above the 100 SMA, it’s still Nasdaq so lots of speculation offset the negative chart effect that usually has, the upper bollinger band is now heading towards the 50 SMA on the one month and six month charts, usually a short term negative, if they can maintain Nasdaq, speculative buying and they move quickly in their review and talk with the FDA maybe the SP recovers, I think it has to be a quick review pivot, not a process of months, for a SP recovery